Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

Helene Mens; Lasse Fjordside; Jannik Fonager; Jan Gerstoft

doi:10.3390/idr14040053

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

Helene Mens^*, Lasse Fjordside, Jannik Fonager, Jan Gerstoft

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

3 Citations (Scopus)

14 Downloads (Pure)

Abstract

HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

Original language	English
Journal	Infectious Disease Reports
Volume	14
Issue number	4
Pages (from-to)	501-504
ISSN	2036-7430
DOIs	https://doi.org/10.3390/idr14040053
Publication status	Published - 2022

Keywords

drug resistance
HIV-1
integrase inhibitors

Access to Document

10.3390/idr14040053

FulltextFinal published version, 705 KBLicence: CC BY

Cite this

@article{0562a91138434f19a791c3815454fae8,

title = "Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART",

abstract = "HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.",

keywords = "drug resistance, HIV-1, integrase inhibitors",

author = "Helene Mens and Lasse Fjordside and Jannik Fonager and Jan Gerstoft",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

doi = "10.3390/idr14040053",

language = "English",

volume = "14",

pages = "501--504",

journal = "Infectious Disease Reports",

issn = "2036-7430",

publisher = "PagePress Publications",

number = "4",

}

TY - JOUR

T1 - Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

AU - Mens, Helene

AU - Fjordside, Lasse

AU - Fonager, Jannik

AU - Gerstoft, Jan

PY - 2022

Y1 - 2022

N2 - HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

AB - HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

KW - drug resistance

KW - HIV-1

KW - integrase inhibitors

U2 - 10.3390/idr14040053

DO - 10.3390/idr14040053

M3 - Journal article

C2 - 35893472

AN - SCOPUS:85134366152

VL - 14

SP - 501

EP - 504

JO - Infectious Disease Reports

JF - Infectious Disease Reports

SN - 2036-7430

IS - 4

ER -